13. 多発性硬化症／視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details

臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

92 trials found

diseases per page:

Showing 1 to 10 of 92 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04971005 (ClinicalTrials.gov)	August 27, 2021	12/8/2020	Ocrelizumab or AlemtuzumabCompared With Autologous Hematopoietic Stem Cell Transplantation in Multip ...	A Randomised Controlled Trial to Compare Ocrelizumab or AlemtuzumabWith Autologous Hematopoietic Ste ...	Relapsing-Remitting Multiple Sclerosis	Drug: Autologous Hematopoietic Stem Cell Transplantation;Drug: Ocrelizumab;Drug: Alemtuzumab	Universitätsklinikum Hamburg-Eppendorf	Neovii Biotech;Clinical Trial Center North (CTC North GmbH & Co. KG)	Recruiting	18 Years	55 Years	All	50	Phase 2	Germany
2	NCT05075499 (ClinicalTrials.gov)	March 20, 2021	6/10/2021	Immune Response to COVID-19 Vaccine in Multiple Sclerosis Patients Treated With Teriflunomide and Al ...	LONGEVITY OF IMMUNE RESPONSE TO COVID-19 VACCINE IN VACCINATED MULTIPLE SCLEROSIS PATIENTS TREATED W ...	Multiple Sclerosis	Biological: COVID-19 vaccination	Sheba Medical Center	Sanofi	Recruiting	18 Years	N/A	All	70	N/A	Israel
3	EUCTR2019-001549-42-GB (EUCTR)	27/03/2020	03/02/2020	Stem cell transplantation versus disease modifying therapy (alemtuzumabor ocrelizumab) for patients ...	A multicentre, randomised controlled trial to evaluate the efficacy of autologous haematopoietic ste ...	Highly active relapsing remitting multiple sclerosis MedDRA version: 20.1;Level: PT;Classification c ...	Product Name: Cyclophosphamide INN or Proposed INN: Cyclophosphamide monohydrate INN or Proposed INN: C ...	Sheffield Teaching Hospitals	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	198	Phase 3	United Kingdom
4	EUCTR2016-001166-29-DE (EUCTR)	18/03/2020	12/08/2019	A randomised controlled trial to compare ocrelizumab or alemtuzumabwith autologous hematopoietic ste ...	A randomised controlled trial to compare ocrelizumab or alemtuzumabwith autologous hematopoietic ste ...	relapsing-remitting multiple sclerosis MedDRA version: 21.1;Level: PT;Classification code 10063399;T ...	Trade Name: Lemtrada Product Name: alemtuzumab INN or Proposed INN: alemtuzumab Other descriptive name: ...	University Medical Centre Hamburg-Eppendorf	NULL	Not Recruiting			Female: yes Male: yes	50	Phase 2	Germany
5	EUCTR2017-001362-25-NL (EUCTR)	30/09/2019	10/09/2019	Randomized study with stem cell transplantation versus standard treatment with alemtuzumab, cladribi ...	Randomized autologous hematopoietic stem cell transplantation versus alemtuzumab, cladribine or ocre ...	Relapsing remitting multiple sclerosis. MedDRA version: 21.1;Level: PT;Classification code 10063399; ...	Trade Name: Cyclophosphamide Product Name: Cyclophosphamide INN or Proposed INN: CYCLOPHOSPHAMIDE Trade ...	Helse Bergen HF, Haukeland University Hospital	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	Denmark;Netherlands
6	NCT03983252 (ClinicalTrials.gov)	July 2019	31/5/2019	Effect of Alemtuzumabon Microglial Activation Positron Emission Tomography (PET) in Multiple Scleros ...	Effect of Alemtuzumabon Microglial Activation Assessed Using Novel [F-18]-Based Positron Emission To ...	Multiple Sclerosis	Drug: [F-18]PBR06	Brigham and Women's Hospital	Genzyme, a Sanofi Company	Not yet recruiting	18 Years	60 Years	All	10	Phase 1/Phase 2	United States
7	EUCTR2017-001362-25-DK (EUCTR)	27/06/2018	21/03/2018	Randomized study with stem cell transplantation versus standard treatment with alemtuzumab, cladribi ...	Randomized autologous hematopoietic stem cell transplantation versus alemtuzumab, cladribine or ocre ...	Relapsing remitting multiple sclerosis. MedDRA version: 21.1;Level: PT;Classification code 10063399; ...	Trade Name: Sendoxane Product Name: Cyclophosphamide Trade Name: Thymoglobuline ® Product Name: Thymoglo ...	Helse Bergen HF, Haukeland University Hospital	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Phase 3	Denmark;Netherlands
8	NCT03477500 (ClinicalTrials.gov)	March 21, 2018	13/2/2018	RCT Comparing Autologous Hematopoietic Stem Cell Transplantation Versus Alemtuzumab in MS	Randomized Autologous Hematopoietic Stem Cell Transplantation Versus Alemtuzumabfor Patients With Re ...	Multiple Sclerosis	Drug: Cyclophosphamide and ATG;Drug: Alemtuzumab	Haukeland University Hospital	NULL	Recruiting	18 Years	50 Years	All	100	Phase 3	Denmark;Netherlands;Norway;Sweden
9	NCT03135249 (ClinicalTrials.gov)	January 1, 2018	12/4/2017	Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis	Sequential Natalizumab - AlemtuzumabTherapy in Patients With Relapsing Forms of Multiple Sclerosis ( ...	Multiple Sclerosis (MS)	Drug: Alemtuzumab	University of Texas Southwestern Medical Center	Genzyme, a Sanofi Company	Active, not recruiting	18 Years	60 Years	All	40	Phase 4	United States
10	EUCTR2016-003100-30-DE (EUCTR)	29/11/2017	07/03/2017	A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumabin Pediatric Patients with RRMS ...	A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safe ...	Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10028245;Term: Multiple sclero ...	Trade Name: Lemtrada Product Name: Lemtrada Product Code: GZ402673 INN or Proposed INN: alemtuzumab	Genzyme Corporation	NULL	Not Recruiting			Female: yes Male: yes	65	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	Portugal;Greece;Spain;Turkey;Austria;Russian Federation;Switzerland;United Kingdom;Italy;France;Czec ...

First Previous1 2 3 4 5…10Next Last